Jul. 29 at 8:12 PM
Bank of America reiterated Elanco Animal Health as its top pick in the animal health sector, maintaining a Buy rating and highlighting the company's clearer growth catalysts and greater potential for earnings upside compared with peers. Analysts believe Elanco has a more defined path for revenue and profit expansion, supported by upcoming product launches, recent regulatory approvals, and opportunities for further estimate revisions.
Recent developments have strengthened the investment case, including a higher price target from TD Cowen, a reaffirmed Overweight rating from Piper Sandler, USDA approval of a new combination vaccine for dogs, and the creation of a
$25 million venture fund focused on animal-health innovation. These initiatives are expected to support long-term growth and enhance Elanco’s competitive position.
$ELAN $IDXX $BAC